Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
Pizzolato
G
G
Department of Neurology, University of Padova School of Medicine, Italy.
Cagnin
A
A
Rossato
A
A
Chierichetti
F
F
Fabbri
M
M
Dam
M
M
Ferlin
G
G
Battistin
L
L
D000328:Adult; D017668:Age of Onset; D000368:Aged; D000375:Aging / Q000378:metabolism; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017072:Neostriatum / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism*; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon
D000978:Antiparkinson Agents; D007457:Iodine Radioisotopes; D017448:Receptors, Dopamine D2; D007980:Levodopa